​​​​​The Genitourinary Site Group at Princess Margaret aims to continuously advance the frontiers of uro-oncology clinical and translational research to provide innovative treatment and management in medical, radiation and surgical oncology.

Currently, our group is leading the International Cancer Genome Consortium, which is mapping the genetic structure of prostate cancer to improve diagnosis and treatment. We are also doing trailblazing work developing minimally invasive prostate ablation therapies such as cryotherapy and high-intensity focused ultrasound.

Our new comprehensive biobank for GU tumours serves as a central repository for high-quality biological specimens and supports research. To build on this function, Dr. Anthony Joshua has taken the lead in developing a prostate cancer clinical annotation database for use in conjunction with the biobank specimens. This database will build on Dr. John Trachtenberg’s existing prostate database platform.

Open Clinical Trials

 
NCT and Other Names
 
Title
 
Principal Investigator
 
Disease Location
Bladder
NCT06305767
V940-005, V940-005,U1111-1292-1952,2023-505658-17-00,INTerpath-005
A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)Dr. Girish KulkarniBladder
NCT05327647
MP-20-2022-6318
A Phase II Trial of Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder CancerDr. Girish KulkarniBladder
NCT06111235
PIVOT-006
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBTDr. Girish KulkarniBladder
NCT05014139
SGN22E-004, EV-104,C5701004,2023-503388-40-00
A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)Dr. Girish KulkarniBladder
NCT04165317
B8011006, CREST,2023-509089-39-00
A Study of Sasanlimab in People With Non-muscle Invasive Bladder CancerDr. Girish KulkarniBladder
NCT05714202
CR109223, 17000139BLC3002,2020-004506-64,2023-507187-39-00
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)Dr. Girish KulkarniBladder
NCT05911295
SGNDV-001, C5731001,2022-501105-12-00
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2Dr. Srikala SridharBladder
NCT03711032
3475-676, MK-3475-676,194713,jRCT2031200390,2018-001967-22
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)Dr. Girish KulkarniBladder
NCT05037279
VRT-BCG-01
Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients with Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC)Dr. Girish KulkarniBladder
NCT03945162
Ruvidar® (TLD-1433) NMIBC PDT
Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") PatientsDr. Girish KulkarniBladder
NCT04752722
EG-70-101
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-NaïveDr. Girish KulkarniBladder
NCT05951179
TARA-002-101-Ph2
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder CancerDr. Girish KulkarniBladder
Kidney / Renal
NCT04011891
18-5885
Comparison of OpeN VErsus RoboTic Partial NephrectomyDr. Robert HamiltonKidney / Renal
NCT03747133
18-5481
SABR for Renal TumorsDr. Rachel GlicksmanKidney / Renal
NCT04987203
AV-951-20-304
Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell CarcinomaDr. Srikala SridharKidney / Renal
NCT05327686
NRG-GU012, NCI-2022-02189,NRG-GU012,NRG-GU012,U10CA180868
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI TrialDr. Andrew McPartlinKidney / Renal
Multiple Sites
NCT03067181
AGCT1531, NCI-2017-00178,AGCT1531,AGCT1531,AGCT1531,U10CA180886
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell TumorsDr. Robert HamiltonMultiple Sites
NCT04223856
SGN22E-003, 2019-004542-15,MK-3475-A39,KEYNOTE KN-A39,jRCT2031200284,CTR20220974
Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial CancerDr. Srikala SridharMultiple Sites
Other
NCT05562830
3475-04A, MK-3475-04A,2023-506384-34-00,U1111-1293-7548,2020-004544-28
A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)Dr. Srikala SridharOther
NCT06124976
H23-02476
Multicenter Clinical Trial of ST-02 for Ablation of Upper Tract Urothelial CarcinomaDr. Girish KulkarniOther
 
Page of 3
View 1 - 20 of 57

To refer a patient to a clinical trial, complete a new patient referral form. Learn more about the Princess Margaret referral process »

For patients: Are you considering taking part in a clinical trial? Learn more about how and why clinical trials are done and what you can expect if you decide to take part in a trial »

https://www.uhn.ca/PrincessMargaret/Education/Continuing_Education_Programs/Pages/continuing_education_programs.aspx
Last reviewed: 12/16/2024
Last modified: 12/17/2024 10:58 AM
Back to Top